Serological tests in the differentiation of staphylococcal and tuberculous bone disease

A. G. TAYLOR, JOSEPHINE COOK, W. J. FINCHAM, AND F. J. C. MILLARD

From the Department of Clinical Pathology, The Institute of Orthopaedics (University of London), Royal National Orthopaedic Hospital, Stanmore, Middlesex, and the Department of Thoracic Medicine, St James’ Hospital, Balham, London

SYNOPSIS The haemagglutination test for antileucocidin is frequently positive in cases of bone tuberculosis in the absence of obvious staphylococcal infection. This test is therefore of little practical use in the differentiation of staphylococcal and tuberculous bone disease, and its use has been discontinued at the Royal National Orthopaedic Hospital.

The antigamma haemolysin test in bone tuberculosis appears to give rise to few false positive results. Our observations confirm that the anti-alpha haemolysin and antigamma haemolysin tests used together reveal about 80% of cases of staphylococcal bone infection on first presentation or relapse.

The measurement of serum antistaphylococcal alpha haemolysin levels is widely used as a test for deep-seated staphylococcal infection, especially in orthopaedic cases. However, it is well recognized that a raised anti-alpha haemolysin titre is found only in about two-thirds of patients who have staphylococcal bone infections (Queneau, Lejeune, Bertoye, Bouvier, Bertrand, and Perrier, 1972). At the Royal National Orthopaedic Hospital during the past 12 years a second staphylococcal antibody, antileucocidin, has also been quantitated as recommended by Towers and Gladstone (1958) and Lack and Towers (1962), using an indirect haemagglutination technique (Towers, 1961). Although lacking specificity this is the only simple method available for the measurement of antileucocidin levels suitable for routine use.

In this paper the value of the antileucocidin test has been assessed in differentiating staphylococcal and tuberculous bone infection and has been found to give a high percentage of false positive results in tuberculosis. The more recently described antistaphylococcal gamma haemolysin test (Taylor and Plommet, 1973) has been further investigated and our results indicate that it is more specific.

Materials and Methods

SELECTION OF CASES

Only those cases in which the causative organism was isolated have been included in the study. Staphylococcal antibody levels were estimated on serum samples obtained at the time the patient was first examined. Patients who had already received antibiotic therapy for more than seven days at this time were excluded from the study.

ESTIMATION OF STAPHYLOCOCCAL ANTIBODY LEVELS

Anti-alpha haemolysin and antileucocidin levels were estimated using the methods described by Lack and Towers (1962). Levels of anti-alpha haemolysin of not more than 2 International units (Iu) per ml of serum were regarded as normal, levels of more than 2 but less than 4 Iu per ml as intermediate, and 4 or more Iu per ml as raised. In the anti-leucocidin test a titre of 0 to 2 units per ml was considered normal, 4 to 8 units per ml as intermediate, and 16 or more units per ml as raised.

Antigamma haemolysin was estimated as described by Taylor and Plommet (1973). In this method 5 units of gamma haemolysin is added in a volume of 0.2 ml to 1 ml of serum dilution in phosphate-buffered saline at pH 6.8. After mixing and standing at room temperature for 10 minutes 0.2 ml of a 12% suspension of washed human group O red cells is added and mixed. The tubes are then incubated at 37°C for 20 minutes and then centrifuged. The endpoint is the last tube showing no haemolysis. Positive and negative control sera are routinely included in the test.
Serological tests in the differentiation of staphylococcal and tuberculous bone disease

In this test a level of up to 2 units per ml of antigamma haemolysin was considered normal, 4 units per ml as intermediate, and 8 units per ml or higher as raised.

BACTERIOLOGICAL METHODS
Cultures of material from lesions were made on blood agar and MacConkey plates; pyogenic organisms were identified by standard methods. In possible cases of tuberculosis smears were stained by Ziehl-Neelsen's method, or were examined microscopically under ultraviolet light using an auramine-rhodamine stain. Material was also inoculated onto Löwenstein's medium and subcutaneously into guinea-pigs which were killed two months later and examined for evidence of tuberculous disease.

Results

ANTILEUCOCIDIN AND ANTI-ALPHA HAEMOLYSIN LEVELS IN BONE TUBERCULOSIS
A total of 37 cases of bone tuberculosis with no evidence of staphylococcal infection has been studied and the results are shown in table I. The average age of the patients was 36 years, ranging from 7 to 68 years. In this series 10 patients (27%) showed raised antileucocidin levels. Five of these had a level of 16 units per ml of serum, two of 32 units, one of 64 units, and two of 256 units per ml. In the anti-alpha haemolysin test four (11%) showed raised antibody levels; three of these were in the range 4-5 Iu per ml and one showed a level of 5 to 8 Iu per ml.

ANTI-ALPHA AND ANTIGAMMA HAEMOLYSIN LEVELS IN TUBERCULOSIS
A further series of 28 patients with bone and pulmonary tuberculosis was studied. The results are shown in table II. The average age of the patients was 43, ranging from 15 to 68 years. (The sera from the 37 patients with bone tuberculosis, which had been used for the anti-alpha and antileucocidin estimations reported above, had been discarded before the introduction of the antigamma haemolysin test.)

Anti-alpha haemolysin levels in this series were all normal, except in three patients, two of whom showed definitely raised levels (4-5 Iu per ml). These were both in the bone group. One patient in the pulmonary group showed an intermediate level of 2-4 Iu per ml.

The antigamma haemolysin levels were raised in four patients, all of whom had levels of 8 units per ml. Two of the four had bone tuberculosis and two had pulmonary tuberculosis. Two patients showed intermediate levels, both in the bone group. The remaining 22 patients all showed normal levels.

Of the four patients showing antigamma levels of 8 units per ml, two had raised anti-alpha levels (4-5 Iu per ml) and one was in the intermediate range (2-4 Iu per ml). The fourth had a normal level. The two patients showing intermediate levels in the antigamma haemolysin test both had normal anti-alpha haemolysin levels. Therefore out of 28 cases of tuberculosis, with no evidence of concurrent staphylococcal infection, there were four false positives in the antigamma haemolysin test, and two of these were also positive in the anti-alpha haemolysin test.

ANTILEUCOCIDIN, ANTI-ALPHA HAEMOLYSIN, AND ANTIGAMMA HAEMOLYSIN IN STAPHYLOCOCCAL OSTEOMYELITIS
In a series of 16 patients with staphylococcal osteomyelitis with an average age of 36 (range 6 to

<table>
<thead>
<tr>
<th>Anti-alpha Haemolysin (Iu/ml)</th>
<th>Antileucocidin (units/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Normal</strong></td>
<td><strong>Intermediate</strong></td>
</tr>
<tr>
<td>0-2</td>
<td>2</td>
</tr>
<tr>
<td>2-4</td>
<td>1</td>
</tr>
<tr>
<td>4 or more</td>
<td></td>
</tr>
</tbody>
</table>

Table I  Anti-alpha haemolysin and antileucocidin in 37 cases of bone tuberculosis

<table>
<thead>
<tr>
<th>Anti-alpha Haemolysin (Iu/ml)</th>
<th>Antigamma Haemolysin (units/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Normal</strong></td>
<td><strong>Intermediate</strong></td>
</tr>
<tr>
<td>0-2</td>
<td>2</td>
</tr>
<tr>
<td>2-4</td>
<td>1</td>
</tr>
<tr>
<td>4 or more</td>
<td>0</td>
</tr>
</tbody>
</table>

Table II  Anti-alpha and antigamma haemolysins in 28 cases of tuberculosis
Table III  Anti-alpha haemolysin, antileucocidin, and antigamma haemolysin in 16 cases of staphylococcal infection of bone

<table>
<thead>
<tr>
<th></th>
<th>Anti-alpha Haemolysin (Iu/ml)</th>
<th>Antileucocidin (units/ml)</th>
<th>Antigamma Haemolysin (units/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Normal 0-2</td>
<td>Intermediate 2-4</td>
<td>Raised 4 or more</td>
</tr>
<tr>
<td></td>
<td>Normal 0-2</td>
<td>Intermediate 4-8</td>
<td>Raised 16 or more</td>
</tr>
<tr>
<td>Number of patients</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>3</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>8</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>4</td>
<td>3</td>
<td>9</td>
</tr>
</tbody>
</table>

1 Not estimated in one case.

Discussion

It would be of immense value if in infective bone lesions the specificity of the host’s immunological response to the invading organism would allow identification of the pathogen by serological techniques. Such an approach would be advantageous where surgical intervention is not indicated. Positive serology would assist the clinician in deciding what antibiotic therapy to prescribe in circumstances where the organism cannot be isolated. Our experience has led us to believe that the serological tests for staphylococcal antibodies, commonly in use at the present time, are inadequate. In the differential diagnosis of tuberculous and staphylococcal bone infection two problems exist. First, in staphylococcal infection the antibody response will not necessarily involve the production of neutralizing antibodies to one specific antigen such as alpha haemolysin. Therefore any one test cannot be expected to reveal more than a proportion of cases in which the staphylococcus is the causative organism. Secondly, in non-staphylococcal infection the ubiquity of the staphylococcus may sometimes be responsible for raised antistaphylococcal antibody levels in the absence of deep-seated infection (Packalen and Bergqvist, 1947).

The first of these problems was recognized by Towers and Gladstone (1958) who proposed the estimation of antileucocidin titres as well as anti-alpha haemolysin levels in the diagnosis of deep-seated staphylococcal infection.

The quantitation of antileucocidin levels was originally dependent upon the ability of this antibody to neutralize leucocidin and thus inhibit its toxicity for human polymorphonuclear leucocytes (Gladstone and van Heyningen, 1957). This bioscopic technique was laborious and prompted the development of a technically simpler haemagglutination method in which a partially purified preparation of leucocidin was used to sensitize tanned sheep red cells (Towers, 1961). This was then used in the assay of antileucocidin levels in the large series of subjects studied by Lack and Towers (1962) and has since been in routine use at the Royal National Orthopaedic Hospital. The advantage of the original bioscopic technique was its high specificity related to the neutralization of the toxin by its specific antibody, and our present results, which show a high proportion of false positives in tuberculosis, can be attributed to the use of the non-specific haemag-
Serological tests in the differentiation of staphylococcal and tuberculous bone disease

Glutination method. Red cells sensitized with highly purified leucocidin were not agglutinated by antisera (W. J. Fincham, unpublished results) and it has not, therefore, been possible to increase the specificity of this indirect method. We suggest that several antigens in the crude leucocidin preparation are involved in the haemagglutination reaction, but that neither of the two proteins which comprise the toxin known as leucocidin is the major agglutinating antigen. The haemagglutination titre probably reflects therefore a summation of a number of antigen-antibody reactions. The very high 'anti-leucocidin' titres we have seen in tuberculous bone disease may well be related to the host's previous experience of the staphylococcus. In the tuberculous patient a significant anamnestic antibody response could be elicited, in the absence of deep-seated staphylococcal infection, due to the adjuvant properties of the tubercle bacillus. The rise in antibody levels to one specific antigen such as alpha haemolysin may, in the large majority of cases of tuberculosis, not be great enough to exceed the normal range. The haemagglutination technique for the estimation of antileucocidin titres, however, due to its non-specific nature, can also measure other staphylococcal antibody levels and therefore give rise to false positive results.

Our results in this paper not only suggest that the specificity of the antileucocidin test is poor, but also that it may reveal only a small proportion of cases of staphylococcal osteomyelitis when used as an initial diagnostic test. Lack and Towers reported a higher proportion of positive results, but they studied the serology over a period of several months in each case. We conclude that the indirect method for the estimation of antileucocidin levels is unsatisfactory for use in conjunction with the anti-alpha haemolysin test in the differentiation of staphylococcal and tuberculous bone infection and the test has been discontinued at the Royal National Orthopaedic Hospital.

The results in this paper, together with those already published (Taylor and Plommet, 1973), suggest that use of both the anti-alpha haemolysin and antigaamma haemolysin tests will provide positive serology in about 80% of patients with untreated or recurrent staphylococcal osteomyelitis at the time of first presentation or relapse.

Previous workers have speculated on the factors which could be responsible for the seronegativity to alpha toxin seen in cases of proven staphylococcal infection. Rogers (1954, 1956) suggested that macroanions, such as chondroitin sulphate, hyaluronic acid, and nucleic acids, interfere with the production of alpha toxin by the staphylococcus, and Bergman (1957) reported that sodium nucleate inhibited its formation. A further possibility is that alpha toxin may form complexes with other molecules, under which conditions it may not give rise to neutralizing antibodies. Recently Kaplan and Wannamaker (1974) showed that lipids extracted from rabbit skin not only inhibit the haemolytic action of streptolysin O, but also suppress the immune response to this streptococcal antigen. Alpha toxin is not inhibited by lipids, but it is possible that it may form complexes with other molecules resulting in an altered antigenicity. The antigaamma haemolysin test resembles the anti-alpha haemolysin test in general principles. Where gamma-lysin is used as an antigen, however, lipids might well be responsible for an immunosuppressive effect, as, like streptolysin O, this toxin is inhibited by cholesterol and phospholipids (Taylor and Bernheimer, 1974). The effect of serum lipids on gamma haemolysin has not yet been studied in detail and our results to date suggest that its non-specific inhibition by serum from patients with tuberculosis is not common. However, the possibility of such inhibition should be borne in mind, as Gallin, Kaye, and O'Leary (1969) found alterations in serum lipids in a number of infections by Gram-negative organisms, and Thoen, Karlson, and Ellefon (1972) have shown that changes in serum lipids occur in rabbits infected with M. bovis and M. avium.

We wish to acknowledge the cooperation of the surgeons of the Royal National Orthopaedic Hospital whose patients have been studied in this investigation. We are grateful to Dr P. Queneau for samples of serum from some patients with bone tuberculosis. Thanks are due to Mr W. H. Bradley who performed the anti-alpha haemolysin and antileucocidin tests. Gamma haemolysin was made available through facilities provided by Dr M. Plommet, Institut National de la Recherche Agronomique, Nouzilly, 37-France, and the expertise of Monsieur G. Béizard is gratefully acknowledged.

The work was supported in part by the Sir William Coxen Trust Fund.

References


Serological tests in the differentiation of staphylococcal and tuberculous bone disease.

A G Taylor, J Cook, W J Fincham and F J Millard

doi: 10.1136/jcp.28.4.284

Updated information and services can be found at: [http://jcp.bmj.com/content/28/4/284](http://jcp.bmj.com/content/28/4/284)

**Email alerting service**

*These include:*

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)